Actively Recruiting
Comparison of the Effectiveness of Oral and Intratympanic Corticosteroid Treatments in Patients Diagnosed With Sudden Sensorineural Hearing Loss
Led by Dr. Lutfi Kirdar Kartal Training and Research Hospital · Updated on 2025-05-13
214
Participants Needed
1
Research Sites
172 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn which one works to treat better in patients with sudden sensorineural hearing loss, oral or intratympanic corticosteroid treatment. The main question it aims to answer is: Which corticosteroid treatment is more effective in patients with sudden sensorineural hearing loss, oral or intratympanic? * In our study, it was planned to divide the treatment schemes compared into two groups. Group 1 included patients who received oral methylprednisolone treatment daily for 2 weeks (48 mg for the first 7 days, 32 mg for the following 2 days, 16 mg for the 2 days, and 8 mg for the last 3 days). Group 2 included patients who received intratympanic 8 mg/2 ml dexamethasone every other day, totally 4 doses. * Visit the clinic after diagnose in first week, second week, first month and second month for checkups and tests ( temporal MR, odimetric results)
CONDITIONS
Official Title
Comparison of the Effectiveness of Oral and Intratympanic Corticosteroid Treatments in Patients Diagnosed With Sudden Sensorineural Hearing Loss
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years of age and older
- Unilateral sudden sensorineural hearing loss developed within 72 hours and lasting 14 days or less
- Affected ear's hearing threshold (PTA at 500-1000-2000-4000 Hz) over 50 dB
- Hearing in affected ear is at least 30 dB lower than healthy ear in 3 frequencies
- Hearing was symmetrical before hearing loss according to patient's statement
- Steroid use, if any, less than 10 days
- Normal cerebellar and vestibular examination
You will not qualify if you...
- History of hearing-related surgery other than ventilation tube
- Previous hearing loss, fluctuating hearing, Meniere's disease, chronic ear infection, cholesteatoma, or otosclerosis
- Age under 18 or over 80
- History of physical barotrauma
- Structural or retrocochlear pathology explaining hearing loss on examination or imaging
- Diagnosed with tuberculosis or receiving tuberculosis prevention treatment
- Having diabetes mellitus, rheumatological disease, atherosclerotic disease
- Serious psychiatric conditions
- Receiving chemotherapy, radiotherapy, or immunosuppressant treatment
- Pancreatitis
- HIV, hepatitis B or C
- Chronic renal failure
- Substance abuse
- Active herpetic lesions
- Severe osteoporosis
- Hearing loss within 4 weeks after general anesthesia
- History of head and neck cancer
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Dr Lütfi Kırdar City Hospital
Istanbul, Kartal, Turkey (Türkiye), 34865
Actively Recruiting
Research Team
K
Koray Islek
CONTACT
V
Volkan Oztemel
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here